ME01926B - 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat - Google Patents
6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleatInfo
- Publication number
- ME01926B ME01926B MEP-2014-154A MEP15414A ME01926B ME 01926 B ME01926 B ME 01926B ME P15414 A MEP15414 A ME P15414A ME 01926 B ME01926 B ME 01926B
- Authority
- ME
- Montenegro
- Prior art keywords
- perldlnyl
- hylbutyl
- amin0
- purin
- maleate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30301010P | 2010-02-10 | 2010-02-10 | |
PCT/EP2011/051830 WO2011098452A1 (en) | 2010-02-10 | 2011-02-08 | 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
EP11709025.8A EP2534149B1 (en) | 2010-02-10 | 2011-02-08 | 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate |
Publications (1)
Publication Number | Publication Date |
---|---|
ME01926B true ME01926B (me) | 2015-05-20 |
Family
ID=43836817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2014-154A ME01926B (me) | 2010-02-10 | 2011-02-08 | 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat |
Country Status (23)
Country | Link |
---|---|
US (1) | US8703754B2 (me) |
EP (1) | EP2534149B1 (me) |
JP (1) | JP5922587B2 (me) |
KR (1) | KR101773541B1 (me) |
CN (1) | CN102753553B (me) |
AU (1) | AU2011214468B2 (me) |
BR (1) | BR112012018904A2 (me) |
CA (1) | CA2786973C (me) |
DK (1) | DK2534149T3 (me) |
EA (1) | EA021048B1 (me) |
ES (1) | ES2525826T3 (me) |
HR (1) | HRP20141258T1 (me) |
IL (1) | IL220845A (me) |
ME (1) | ME01926B (me) |
MX (1) | MX2012009316A (me) |
PL (1) | PL2534149T3 (me) |
PT (1) | PT2534149E (me) |
RS (1) | RS53745B1 (me) |
SG (1) | SG182471A1 (me) |
SI (1) | SI2534149T1 (me) |
SM (1) | SMT201400196B (me) |
WO (1) | WO2011098452A1 (me) |
ZA (1) | ZA201205995B (me) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
WO2010064146A2 (en) | 2008-12-02 | 2010-06-10 | Chiralgen, Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
KR101885383B1 (ko) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | 신규한 핵산 프로드러그 및 그의 사용 방법 |
US8507507B2 (en) | 2009-10-22 | 2013-08-13 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
JP6128529B2 (ja) | 2011-07-19 | 2017-05-17 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | 官能化核酸の合成のための方法 |
RU2631482C2 (ru) * | 2011-07-22 | 2017-09-22 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Композиция |
JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | キラル制御 |
CA2879066C (en) * | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
DK2872485T3 (da) | 2012-07-13 | 2021-03-08 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
AU2013305790B2 (en) | 2012-08-24 | 2016-09-08 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
US9428512B2 (en) | 2012-11-20 | 2016-08-30 | Glaxosmithkline Llc | Compounds |
KR20150085080A (ko) | 2012-11-20 | 2015-07-22 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
ES2639789T3 (es) | 2012-11-20 | 2017-10-30 | Glaxosmithkline Llc | Compuestos novedosos |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
SG10201912897UA (en) | 2014-01-16 | 2020-02-27 | Wave Life Sciences Ltd | Chiral design |
ES2944885T3 (es) * | 2014-08-29 | 2023-06-26 | Corium Pharma Solutions Inc | Matriz de microestructuras para administración de agentes activos |
BE1023340B1 (fr) * | 2014-11-13 | 2017-02-08 | Glaxosmithkline Biologicals S.A. | Composes |
US20220026404A1 (en) * | 2018-11-28 | 2022-01-27 | Shimadzu Corporation | Analyzing method for azo compound |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
AU679511B2 (en) | 1993-03-17 | 1997-07-03 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
EP1065213A3 (en) | 1999-07-02 | 2003-11-05 | Japan Tobacco Inc. | HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
ID30204A (id) | 1999-12-27 | 2001-11-15 | Japan Tobacco Inc | Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
CN1533390A (zh) | 2001-03-19 | 2004-09-29 | СҰҩƷ��ҵ��ʽ���� | 包含三氮杂螺[5.5]十一烷衍生物作为活性成分的药物组合物 |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム (カナダ) リミテッド | ウイルスポリメラーゼインヒビター |
CA2481502A1 (en) | 2002-04-04 | 2003-10-16 | Achillion Pharmaceuticals, Inc. | Hcv antiviral and cytotoxicity drug screening assay |
DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
BR0315417A (pt) | 2002-10-24 | 2005-08-16 | Glaxo Group Ltd | Derivados 1-acil-pirrolidina para o tratamento de infecções virais |
JP2006511552A (ja) | 2002-12-13 | 2006-04-06 | スミスクライン ビーチャム コーポレーション | Ccr5拮抗薬としてのピロリジンおよびアゼチジン化合物 |
JP2006514950A (ja) | 2002-12-13 | 2006-05-18 | スミスクライン ビーチャム コーポレーション | Ccr5拮抗薬としてのシクロプロピル化合物 |
DE60323133D1 (de) | 2002-12-13 | 2008-10-02 | Smithkline Beecham Corp | Cyclohexylverbindungen als ccr5-antagonisten |
EP1581530A1 (en) | 2002-12-13 | 2005-10-05 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
WO2004055011A1 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Heterocyclic compounds as ccr5 antagonists |
RU2005118407A (ru) | 2002-12-13 | 2006-03-10 | СмитКлайн Бичем Корпорейшн (US) | Производные пиперидина в качестве антагонистов ccr5 |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
PL1699512T3 (pl) | 2003-11-03 | 2012-11-30 | Glaxo Group Ltd | Urządzenie do dozowania płynów |
US7582770B2 (en) | 2004-02-20 | 2009-09-01 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
CA2564175A1 (en) | 2004-04-28 | 2005-11-10 | Arrow Therapeutics Limited | Chemical compounds |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
UA88909C2 (ru) | 2004-08-18 | 2009-12-10 | Пфайзер Инк. | Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с, фармацевтическая композиция на их основе и их применение |
WO2006026394A2 (en) | 2004-08-27 | 2006-03-09 | 3M Innovative Properties Company | Method of eliciting an immune response against hiv |
GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
AP2358A (en) | 2005-05-09 | 2012-01-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use. |
WO2007034881A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
EP2125792B1 (en) | 2007-02-19 | 2010-12-01 | GlaxoSmithKline LLC | Purine derivatives as immunomodulators |
PT2132209E (pt) | 2007-03-19 | 2014-04-15 | Astrazeneca Ab | Compostos de 8-oxo-adenina substituídos na posição 9, como moduladores do recetor de tipo ¿toll¿ (tlr7) |
PE20091156A1 (es) * | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
US8777708B2 (en) | 2008-06-27 | 2014-07-15 | Microsoft Corporation | Targeting control in a simulated environment |
UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
-
2011
- 2011-02-08 ES ES11709025.8T patent/ES2525826T3/es active Active
- 2011-02-08 EA EA201290631A patent/EA021048B1/ru not_active IP Right Cessation
- 2011-02-08 WO PCT/EP2011/051830 patent/WO2011098452A1/en active Application Filing
- 2011-02-08 PT PT117090258T patent/PT2534149E/pt unknown
- 2011-02-08 DK DK11709025.8T patent/DK2534149T3/da active
- 2011-02-08 KR KR1020127023687A patent/KR101773541B1/ko active IP Right Grant
- 2011-02-08 BR BR112012018904-2A patent/BR112012018904A2/pt not_active IP Right Cessation
- 2011-02-08 EP EP11709025.8A patent/EP2534149B1/en active Active
- 2011-02-08 AU AU2011214468A patent/AU2011214468B2/en not_active Ceased
- 2011-02-08 CA CA2786973A patent/CA2786973C/en not_active Expired - Fee Related
- 2011-02-08 CN CN201180009082.0A patent/CN102753553B/zh not_active Expired - Fee Related
- 2011-02-08 SI SI201130364T patent/SI2534149T1/sl unknown
- 2011-02-08 US US13/578,020 patent/US8703754B2/en not_active Expired - Fee Related
- 2011-02-08 ME MEP-2014-154A patent/ME01926B/me unknown
- 2011-02-08 PL PL11709025T patent/PL2534149T3/pl unknown
- 2011-02-08 MX MX2012009316A patent/MX2012009316A/es active IP Right Grant
- 2011-02-08 RS RS20150005A patent/RS53745B1/en unknown
- 2011-02-08 JP JP2012552369A patent/JP5922587B2/ja active Active
- 2011-02-08 SG SG2012051140A patent/SG182471A1/en unknown
-
2012
- 2012-07-10 IL IL220845A patent/IL220845A/en not_active IP Right Cessation
- 2012-08-08 ZA ZA2012/05995A patent/ZA201205995B/en unknown
-
2014
- 2014-12-23 HR HRP20141258AT patent/HRP20141258T1/hr unknown
- 2014-12-30 SM SM201400196T patent/SMT201400196B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2534149A1 (en) | 2012-12-19 |
EA201290631A1 (ru) | 2013-03-29 |
AU2011214468B2 (en) | 2015-05-28 |
AU2011214468A1 (en) | 2012-08-09 |
SMT201400196B (it) | 2015-01-15 |
PT2534149E (pt) | 2014-12-23 |
SI2534149T1 (sl) | 2015-02-27 |
KR101773541B1 (ko) | 2017-08-31 |
CN102753553A (zh) | 2012-10-24 |
ES2525826T3 (es) | 2014-12-30 |
RS53745B1 (en) | 2015-06-30 |
HRP20141258T1 (hr) | 2015-02-27 |
CA2786973A1 (en) | 2011-08-18 |
CA2786973C (en) | 2018-04-10 |
WO2011098452A1 (en) | 2011-08-18 |
ZA201205995B (en) | 2014-01-29 |
DK2534149T3 (da) | 2015-01-05 |
IL220845A (en) | 2016-08-31 |
US20120308609A1 (en) | 2012-12-06 |
SG182471A1 (en) | 2012-08-30 |
JP5922587B2 (ja) | 2016-05-24 |
CN102753553B (zh) | 2016-03-30 |
EA021048B1 (ru) | 2015-03-31 |
BR112012018904A2 (pt) | 2020-09-01 |
MX2012009316A (es) | 2012-09-12 |
JP2013519645A (ja) | 2013-05-30 |
PL2534149T3 (pl) | 2015-03-31 |
EP2534149B1 (en) | 2014-10-15 |
US8703754B2 (en) | 2014-04-22 |
KR20120135408A (ko) | 2012-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME01926B (me) | 6-am in0-2-{[(1s)-1-meti lbuti l]oksi }-9-[5-(1-piperidinil) pentil]-7,9-di hidro-8h- purin-8-0n maleat | |
EP2589897A4 (en) | Touch-control multifunctional refrigerating cup holder | |
ZA201300429B (en) | Non-energetics based detonator | |
EP2626474A4 (en) | Hybrid construction machine | |
EP2479351A4 (en) | Hybrid construction machine | |
EP2568877A4 (en) | Electrode displacement determination | |
EP2578756A4 (en) | Hybrid construction machine | |
EP2566314A4 (en) | Manufacturing-work machine | |
EP2630122A4 (en) | ARYLAMID DERIVATIVES AS TTX-S BLOCKERS | |
EP2615212A4 (en) | Hybrid construction machine | |
EP2582704A4 (en) | Asenapine MALEATE | |
EP2565330A4 (en) | Construction machine | |
EP2581501A4 (en) | Construction machine | |
EP2628860A4 (en) | Hybrid construction machine | |
EP2647771A4 (en) | Construction machine | |
EP2530207A4 (en) | Hybrid construction machine | |
EP2628859A4 (en) | Construction machine | |
AU2010101360A4 (en) | Kiteboarding Dual Board Bag | |
AU2013204145B2 (en) | Pure erlotinib | |
AU2010904244A0 (en) | Wishing well bag | |
AU2010905063A0 (en) | Vending machine | |
AU2010901977A0 (en) | Oil-gas separator for operation in deep waters | |
AU2010903186A0 (en) | Evaporator saver | |
AU2010905475A0 (en) | Ice machine | |
AU2010901004A0 (en) | Garment for ostymates |